Interferon-alpha in tumor immunity and immunotherapy

被引：285
作者：
Belardelli, F
Ferrantini, M
Proietti, E
Kirkwood, JM
机构：
[1] Ist Super Sanita, Virol Lab, I-00161 Rome, Italy
[2] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA
来源：
CYTOKINE & GROWTH FACTOR REVIEWS | 2002年 / 13卷 / 02期
关键词：
interferon-alpha; tumor; immunity; immunotherapy;
D O I：
10.1016/S1359-6101(01)00022-3
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Interferon-alpha (IFN-alpha) is a pleiotropic cytokine belonging to type I IFN, currently used in cancer patients. Early studies in mouse tumor models have shown the importance of host immune mechanisms in the generation of a long-lasting antitumor response to type I IFN. Recent studies have underscored new immunomodulatory effects of IFN-alpha including activities on T and dendritic cells, which may explain IFN-induced tumor immunity. Reports on new immune correlates in cancer patients responding to IFN-alpha represent additional evidence on the importance of the interactions of IFN-a with the immune system for the generation of durable antitumor response, This knowledge, together with results from studies on genetically modified tumor cells expressing IFN-alpha, suggest novel strategies for using these cytokines in cancer immunotherapy and in particular the use of IFN-alpha as an immune adjuvant for the development of cancer vaccines. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：119 / 134
页数：16
相关论文
共 107 条
[1]   INTERFERONS IN THE THERAPY OF SOLID TUMORS [J].
AGARWALA, SS ;
KIRKWOOD, JM .
ONCOLOGY, 1994, 51 (02) :129-136
[2]   Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs [J].
Albert, ML ;
Sauter, B ;
Bhardwaj, N .
NATURE, 1998, 392 (6671) :86-89
[3]  
Balch CM, 2000, CANCER-AM CANCER SOC, V88, P1484, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO
[4]  
2-D
[5]   Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system [J].
Balch, CM ;
Soong, SJ ;
Gershenwald, JE ;
Thompson, JF ;
Reintgen, DS ;
Cascinelli, N ;
Urist, M ;
McMasters, KM ;
Ross, MI ;
Kirkwood, JM ;
Atkins, MB ;
Thompson, JA ;
Coit, DG ;
Byrd, D ;
Desmond, R ;
Zhang, YT ;
Liu, PY ;
Lyman, GH ;
Morabito, A .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3622-3634
[6]  
Belardelli F, 1998, CANCER RES, V58, P5795
[7]   INJECTION OF MICE WITH ANTIBODY TO INTERFERON RENDERS PERITONEAL-MACROPHAGES PERMISSIVE FOR VESICULAR STOMATITIS-VIRUS AND ENCEPHALOMYOCARDITIS VIRUS [J].
BELARDELLI, F ;
VIGNAUX, F ;
PROIETTI, E ;
GRESSER, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (02) :602-606
[8]   The neglected role of type I interferon in the T-cell response: Implications for its clinical use [J].
Belardelli, F ;
Gresser, I .
IMMUNOLOGY TODAY, 1996, 17 (08) :369-372
[9]   ANTI-TUMOR EFFECTS OF INTERFERON IN MICE INJECTED WITH INTERFERON-SENSITIVE AND INTERFERON-RESISTANT FRIEND-LEUKEMIA CELLS .1. [J].
BELARDELLI, F ;
GRESSER, I ;
MAURY, C ;
MAUNOURY, MT .
INTERNATIONAL JOURNAL OF CANCER, 1982, 30 (06) :813-820
[10]   ROLE OF INTERFERONS AND OTHER CYTOKINES IN THE REGULATION OF THE IMMUNE-RESPONSE [J].
BELARDELLI, F .
APMIS, 1995, 103 (03) :161-179
12345678910